High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.
Regression in the radial growth phase (RGP) of primary cutaneous melanomas is common and has been shown to be an adverse prognostic factor. However, the underlying mechanism is unclear. We performed dual immunohistochemical staining of podoplanin and S-100 on paraffin tissues from 321 patients with vertical growth phase primary melanomas, who had 10 years or more of follow-up. Lymphatic vessel density (LD) and lymphatic invasion (LI) were quantified and documented. The time to first metastasis and melanoma-specific death (MSD) from the date of definite treatment were analyzed using univariate and multivariate Cox models. Among the 116 vertical growth phase melanomas that had regression in the adjacent RGP, 75 (23%) were classified as complete and 41 (13%) were classified as partial. LD was significantly higher (P<0.001) in the 75 lesions with complete regression (mean±SD, 23.7±12.3/mm²) compared with the 41 lesions with partial regression (15.5±7.1/mm²) and was lower in 155 areas of the adjacent normal dermis (7.3±3.5/mm²) and 69 areas of the distant normal dermis (5.5±2.6/mm²). Patients whose lesions had areas of complete regression with LI and either high or low LD or had no LI with high LD, had shorter time to first metastasis (hazard ratio=2.5, 3.8, and 2.5, respectively) and increased risk of melanoma-specific death (hazard ratio=3.1, 1.3 and 3.0, respectively) than those with no LI, and low LD or those without areas of complete regression. These data indicate that complete RGP regression is associated with significantly increased LD. In addition, the adverse prognostic effect of RGP regression is at least partially mediated through lymphangiogenesis and LI in this area.
Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea.
Sook Jung
SJ
Yun
Phyllis A
PA
Gimotty
Wei-Ting
WT
Hwang
Peter
P
Dawson
Patricia
P
Van Belle
David E
DE
Elder
Rosalie
R
Elenitsas
Lynn
L
Schuchter
Paul J
PJ
Zhang
DuPont
D
Guerry
Xiaowei
X
Xu
D014408:Biomarkers, Tumor / Q000378:metabolism; D015331:Cohort Studies; D020405:Dermis; D018450:Disease Progression; D004729:Endothelium, Lymphatic / Q000378:metabolism / Q000473:pathology; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007124:Immunoenzyme Techniques; D042583:Lymphangiogenesis; D008207:Lymphatic Metastasis; D042601:Lymphatic Vessels / Q000473:pathology*; D008297:Male; D008545:Melanoma / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D008562:Membrane Glycoproteins / Q000378:metabolism; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D012189:Retrospective Studies; D009418:S100 Proteins / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D000098853:Podoplanin
D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D009418:S100 Proteins; C117468:PDPN protein, human; D000098853:Podoplanin
J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904
2593166
Am J Dermatopathol. 2003 Oct;25(5):371-6
14501285
Arch Dermatol. 2005 Apr;141(4):440-4
15837861
J Clin Pathol. 2006 Feb;59(2):166-73
16443733
J Cutan Pathol. 2009 Jul;36(7):772-80
19032379
Hum Pathol. 2008 Jun;39(6):901-9
18440591
Am J Dermatopathol. 2008 Apr;30(2):178-81
18360126
Clin Cancer Res. 2003 Jan;9(1):250-6
12538477
Lab Invest. 2002 Sep;82(9):1255-7
12218087
J Cutan Pathol. 2004 Nov;31(10):672-7
15491327
J Clin Pathol. 2008 Mar;61(3):297-300
17675538
Am J Pathol. 2003 Jun;162(6):1951-60
12759251
Virchows Arch A Pathol Anat Histopathol. 1992;420(2):113-5
1549899
J Pathol. 1986 Jun;149(2):89-95
2426432
Lancet. 1986 Feb 8;1(8476):307-10
2868172
J Cell Physiol. 2008 Aug;216(2):347-54
18481261
Am J Pathol. 1993 Jul;143(1):99-104
7686347
Cancer Res. 2001 Mar 1;61(5):1786-90
11280723
Am J Pathol. 2002 Sep;161(3):947-56
12213723
Br J Cancer. 2004 Feb 9;90(3):693-700
14760386
Histopathology. 1983 Sep;7(5):673-80
6629343
Virchows Arch A Pathol Anat Histopathol. 1985;408(2-3):241-7
3936263
Eur J Cancer. 2004 Feb;40(3):358-64
14746853
Mod Pathol. 2005 Sep;18(9):1232-42
15803182
Br J Dermatol. 2003 Sep;149(3):662-3
14511013
Arch Dermatol. 1987 Oct;123(10):1326-30
3662564
Histopathology. 1992 Apr;20(4):315-22
1577409